Pimavanserin

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Agitation and Aggression in Alzheimer's Disease

Drug Information

Target Indication

Agitation and Aggression in Alzheimer's Disease

Clinical Trial

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ACAD

ACADIA Pharmaceuticals Inc.

Related Pipeline

Lewy Body Dementia Psychosis

Dementia-related Psychosis

Parkinson's Disease Psychosis

Rett Syndrome

Parkinson's Disease Psychosis